BR112012015967A2 - uso de compostos de fórmula geral (i) e composição farmacêutica - Google Patents

uso de compostos de fórmula geral (i) e composição farmacêutica

Info

Publication number
BR112012015967A2
BR112012015967A2 BR112012015967A BR112012015967A BR112012015967A2 BR 112012015967 A2 BR112012015967 A2 BR 112012015967A2 BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 A2 BR112012015967 A2 BR 112012015967A2
Authority
BR
Brazil
Prior art keywords
formula
pharmaceutical composition
compounds
carbolines
alkyl
Prior art date
Application number
BR112012015967A
Other languages
English (en)
Other versions
BR112012015967B1 (pt
Inventor
Hans Rommelspacher
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of BR112012015967A2 publication Critical patent/BR112012015967A2/pt
Publication of BR112012015967B1 publication Critical patent/BR112012015967B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Abstract

uso de composto de fórmula geral (i) e composição farmacêutica a presente invenção é dirigida à <225>-carbolinas, 9-alquil-<225>-carbolinas preferidas (9-alquil-<225>-bc), sua fabricação assim como seu uso na profilaxia e tratamento de danos de audição , zumbido, vertigem e trauma acústico agudo distúrbio vestibular assim como composições farmacêuticas contendo estas <225>-carbolinas.
BR112012015967A 2009-12-28 2010-12-28 uso de compostos de fórmula geral (i) e composição farmacêutica BR112012015967B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (2)

Publication Number Publication Date
BR112012015967A2 true BR112012015967A2 (pt) 2016-04-19
BR112012015967B1 BR112012015967B1 (pt) 2019-08-27

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015967A BR112012015967B1 (pt) 2009-12-28 2010-12-28 uso de compostos de fórmula geral (i) e composição farmacêutica

Country Status (17)

Country Link
US (1) US9107914B2 (pt)
EP (1) EP2519238B1 (pt)
JP (1) JP5627705B2 (pt)
KR (1) KR20120098855A (pt)
CN (1) CN102844029A (pt)
AU (1) AU2010338669A1 (pt)
BR (1) BR112012015967B1 (pt)
CA (1) CA2785233C (pt)
DE (1) DE112010005017A5 (pt)
IL (1) IL220661A (pt)
IN (1) IN2012DN05066A (pt)
MX (1) MX2012007678A (pt)
NZ (1) NZ600478A (pt)
RU (1) RU2012132429A (pt)
SG (1) SG181599A1 (pt)
WO (1) WO2011079841A1 (pt)
ZA (1) ZA201204476B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ713219A (en) 2013-03-14 2017-04-28 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
CA2899247C (en) 2013-03-14 2023-04-04 Osteoqc Inc. Alkyl-amine harmine derivatives for promoting bone growth
EP2853533A1 (de) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
CA3109104A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Fluoro .beta.-carboline compounds
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
EP3772515A1 (en) 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ATE229954T1 (de) * 1998-06-12 2003-01-15 Sod Conseils Rech Applic Betacarbolinverbindungen
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
EP2519238A1 (de) 2012-11-07
IL220661A (en) 2016-03-31
MX2012007678A (es) 2012-09-12
US20130028958A1 (en) 2013-01-31
DE112010005017A5 (de) 2012-10-04
EP2519238B1 (de) 2014-08-13
KR20120098855A (ko) 2012-09-05
CA2785233A1 (en) 2011-06-07
ZA201204476B (en) 2014-01-29
WO2011079841A1 (de) 2011-07-07
US9107914B2 (en) 2015-08-18
SG181599A1 (en) 2012-07-30
AU2010338669A1 (en) 2012-06-21
JP5627705B2 (ja) 2014-11-19
BR112012015967B1 (pt) 2019-08-27
NZ600478A (en) 2013-10-25
RU2012132429A (ru) 2014-02-10
CN102844029A (zh) 2012-12-26
JP2013515752A (ja) 2013-05-09
IL220661A0 (en) 2012-08-30
CA2785233C (en) 2018-10-09
IN2012DN05066A (pt) 2015-10-09

Similar Documents

Publication Publication Date Title
BR112012015967A2 (pt) uso de compostos de fórmula geral (i) e composição farmacêutica
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
UA111770C2 (uk) Інгібітори бромдомену
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201100503A1 (ru) Глюкозидные производные и их применения
CL2012001391A1 (es) Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios.
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
UA108219C2 (uk) Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти)
EA201590748A1 (ru) Противовирусные соединения против rsv
BR112015022861A8 (pt) inibidores de bromodomínio
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
BR112015018663A2 (pt) derivados de piridazinona-amidas
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
TR201904614T4 (tr) Novel pyrazole derivative.
DOP2014000133A (es) Triazolopiridinas sustituidas
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201170922A1 (ru) Производные сульфонамида
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
UY33452A (es) Triazolopiridinas sustituidas
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS